Core Viewpoint - Haohai Biological Technology (昊海生科) plans to invest in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. (瑞济生物) to enter the high-value biological amniotic membrane market despite experiencing a decline in revenue and net profit [1][4]. Group 1: Investment Details - Haohai will acquire a total of 19.8% of Ruiji Biological's shares through a framework agreement, paying 38.35 million yuan and 4.76 million yuan in three phases for 8.4661 million shares and 1.0499 million shares respectively [1][3]. - The transaction price is set at 4.53 yuan per share, based on the market price before Ruiji Biological's delisting from the National Equities Exchange and Quotations [3][9]. Group 2: Company Background - Ruiji Biological, established in 2002, specializes in the production and sale of biological amniotic membranes, which are classified as Class III medical devices used in orthopedic and ophthalmic fields [1][3]. - Haohai aims to enhance its product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors by obtaining distribution rights for Ruiji's products in China [3][9]. Group 3: Financial Performance - Ruiji Biological reported revenues of approximately 46.36 million yuan and 46.09 million yuan for 2024 and the first three quarters of 2025, respectively, with net losses of 11.77 million yuan and 11.29 million yuan [4][10]. - Haohai's revenue for the first three quarters of this year was about 1.899 billion yuan, a year-on-year decrease of 8.47%, with a corresponding net profit of approximately 305 million yuan, down 10.63% year-on-year [4][10]. Group 4: Risks and Challenges - The transaction does not include performance commitments or earn-out arrangements, which means there are risks associated with potential underperformance of Ruiji Biological [4][10]. - Market conditions and sales channels may affect the sales performance of the acquired products, posing risks of reduced investment returns and failure to achieve acquisition objectives [5][10].

Core Viewpoint - The company Haohai Biological Technology (688366.SH) plans to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for RMB 38.35 million, enhancing its presence in the high-value medical device sector focused on biological amniotic membranes [1] Group 1: Company Acquisition - Haohai Biological Technology will use its own funds to acquire 8.4661 million shares from shareholders Miao Jiuchang and Miao Chunyu [1] - The acquisition allows Haohai to gain distribution rights for Ruiji's products within China, thereby expanding its product portfolio in the ophthalmology and orthopedics fields [1] Group 2: Business Overview of Ruiji - Ruiji Biological was established in 2002 and specializes in the production and sale of biological amniotic membranes, which are classified as Class III medical devices [1] - The main products include convex and concave amniotic membranes, biological orthopedic amniotic membranes, and wet biological amniotic membranes, used primarily in orthopedic and ophthalmic applications [1] Group 3: Strategic Implications - The acquisition is expected to provide important technical and material foundations for Haohai's research and development in regenerative medicine and tissue engineering [1] - The human-derived biological characteristics of the amniotic materials are anticipated to drive innovation and technological upgrades in subsequent product offerings [1]

Core Viewpoint - Company Haohai Biological Technology (688366.SH) plans to acquire 8.4661 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for RMB 38.3515 million, representing 19.8% of Ruiji's total share capital [1] Group 1: Company Overview - Jiangxi Ruiji was established in 2002 and specializes in the production and sales of biological amniotic membranes [1] - The main products include convex and concave amniotic membrane products, biological orthopedic amniotic membrane products, and wet biological amniotic membrane products, classified as Class III medical devices [1] Group 2: Market and Product Applications - The products are primarily used in orthopedic and ophthalmic fields, including tendon repair, treatment of ocular burns and injuries, and support after lacrimal duct obstruction [1] - The acquisition allows the company to gain distribution rights for Ruiji's products in China, entering the high-value medical device sector of biological amniotic membranes [1] Group 3: Strategic Implications - The acquisition is expected to effectively supplement the company's existing product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [1] - Ruiji's amniotic membrane materials possess human-derived biological characteristics, providing essential technical and material foundations for the company's research and development in regenerative medicine and tissue engineering [1] - This move is anticipated to drive subsequent product innovation and technological upgrades for the company [1]

Core Viewpoint - Haohai Biological Technology (06826.HK) announced a share purchase agreement to acquire approximately 19.8% of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. and an additional 2.4554% by a personal buyer, which will enhance its presence in the high-value medical device market for orthopedics and ophthalmology [1] Group 1 - The acquisition will be completed in three phases between 2025 and 2026, with total cash consideration of RMB 38,351,487.36 for Buyer I and RMB 4,755,979.05 for Buyer II [1] - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and injury repair, and tear duct obstruction support [1] - By investing in the target company, the group aims to enter the high-value biological amniotic membrane market, complementing its existing product portfolio and expanding its business layout in orthopedics and ophthalmology [1] Group 2 - The amniotic materials held by the target company possess human-derived biological characteristics, providing the group with critical technology and material foundations in regenerative medicine and tissue engineering [1] - This investment is expected to drive subsequent product innovation and technological upgrades within the group [1]

Group 1 - The core point of the article is that Haohai Biological Technology (06826.HK) has entered into a share purchase agreement to acquire approximately 19.8% of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. and an additional 2.4554% by a personal buyer, with the total cash consideration amounting to RMB 38,351,487.36 for the first buyer and RMB 4,755,979.05 for the second buyer [1] Group 2 - The share transfer will be completed in three phases between 2025 and 2026 [1] - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and lesion repair, and tear duct obstruction support [1] - By investing in the target company and obtaining distribution rights for its products in China, the group aims to enter the high-value medical device market of biological amniotic membranes, enhancing its existing product portfolio and expanding its business in orthopedics and ophthalmology [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the group with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive future product innovation and technological upgrades [1]

Core Viewpoint - Haohai Biological Technology (06826) announced plans to acquire approximately 19.8% and 2.4554% stakes in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for approximately 38.35 million yuan and 4.756 million yuan respectively, aiming to enter the high-value medical device market in China [1] Group 1 - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and injury lesion repair, and tear duct obstruction [1] - By investing in the target company and obtaining distribution rights for its products in China, the company aims to enhance its product portfolio and expand its business layout in the orthopedic and ophthalmic fields [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the company with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive subsequent product innovation and technological upgrades [1]

Core Viewpoint - Haohai Biological Technology (06826) plans to acquire approximately 19.8% and 2.4554% equity stakes in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for approximately 38.35 million yuan and 4.756 million yuan respectively, aiming to enter the high-value medical device market of biological amniotic membranes and expand its business in orthopedics and ophthalmology [1] Group 1 - The target company's products are primarily used in orthopedics and ophthalmology for tendon injury repair, ocular surface burns, wound and lesion repair, and support after lacrimal duct obstruction [1] - By investing in the target company and obtaining distribution rights for its products in China, the company will enhance its existing product portfolio and expand its business layout in the orthopedic and ophthalmic fields [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the company with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive subsequent product innovation and technological upgrades [1]